Radiotherapy Dose De-escalation in HPV-Associated Cancers of the Oropharynx (NCT04667585)
Radiotherapy Dose De-escalation in HPV-Associated Cancers of the Oropharynx Using Metabolic Signature From Interim 18FDG-PET/CT
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to use intra-treatment 18FDG-PET/CT during definitive radiation therapy for human papillomavirus (HPV)-related oropharyngeal cancer (OPC) as an imaging biomarker to identify and select patients with a favorable response for chemoradiation dose de-escalation. This study will prospectively evaluate the clinical outcomes for patients undergoing dose de-escalation.
Who can join: Review the eligibility criteria below.
Location: Duke University Medical Center — Durham, North Carolina
Age range: 18 Years
🧪 Interventions in This Study
- De-escalated radiation dose (RADIATION)
- Standard radiation dose (RADIATION)
- 18 fluorodeoxyglucose (FDG)-positron emission tomography (PET)-Computed Tomography (CT) (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (2 Sites)
- Duke University Medical Center — Durham, North Carolina
- Duke Raleigh Hospital — Raleigh, North Carolina
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Oropharynx Cancer
- Neoadjuvant Immunoradiotherapy With Evorpacept and Pembrolizumab in HPVOPC (Human Papilloma Virus Oropharynx Cancer) — La Jolla, California
- Trial of Individualized Adaptive RT in HPV-related High Risk Oropharynx Cancer — Ann Arbor, Michigan
- Dose Adjusted Chemoradiotherapy in HPV-Associated Oropharynx Cancer of the Elderly — Jacksonville, Florida
- Lymphoscintigraphy Directed Elective Neck Radiation for p16+ Favorable Risk Oropharynx Cancer — Philadelphia, Pennsylvania
- Transoral Surgical Resection Followed by De-escalated Adjuvant IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer — Pittsburgh, Pennsylvania
Explore by condition: All Oropharynx Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.